Service d'endocrinologie diabétologie nutrition, CHU Grenoble-Alpes, CS 10217, boulevard de la Chantourne, 38043 Grenoble cedex 9, France.
Service de médecine interne, endocrinologie et nutrition, hôpitaux universitaires de Strasbourg, 67098 Strasbourg cedex, France.
Ann Endocrinol (Paris). 2017 Dec;78(6):490-494. doi: 10.1016/j.ando.2017.10.010. Epub 2017 Nov 27.
The prevalence of primary adrenal insufficiency is estimated at between 82-144/million, with auto-immunity being the most common cause in adults and genetic causes, especially enzyme defects, being the most common cause in children. The prevalence of secondary adrenal deficiency is estimated to be between 150-280/million. The most frequent occurrence is believed to be corticosteroid-induced insufficiency, despite the incidence of clinically relevant deficiency after cessation of glucocorticoid treatment being widely debated. Data on mortality in adrenal insufficiency are contradictory, with studies from Sweden suggesting a two-fold increase in comparison to the general population, but this is not consistently reported in all studies. However, increased mortality has been consistently reported in young patients, associated with infection and/or acute adrenal insufficiency. Acute adrenal deficiency (adrenal crisis) occurs in primary as well as secondary adrenal insufficiency. Its incidence, mostly determined in retrospective studies, is estimated in Europe at 6-8/100 patients/year. A prospective study reported 0.5 deaths/100 patient-years from adrenal crisis. Long-term morbidity of adrenal insufficiency is not well-established, the increased cardiovascular risk or bone demineralization which are not consistently reported may also be due to a supraphysiological glucocorticoid replacement therapy. However, alteration in quality of life, both in physical and mental health components, has been demonstrated by several studies in both primary and secondary adrenal insufficiency.
原发性肾上腺功能不全的患病率估计为 82-144/百万,自身免疫是成年人最常见的原因,而遗传原因,特别是酶缺陷,是儿童最常见的原因。继发性肾上腺功能不全的患病率估计为 150-280/百万。最常见的发生是皮质类固醇诱导的功能不全,尽管停止糖皮质激素治疗后临床相关缺乏的发生率存在广泛争议。关于肾上腺功能不全的死亡率数据存在矛盾,来自瑞典的研究表明,与普通人群相比,死亡率增加了一倍,但并非所有研究都一致报告。然而,在年轻患者中,感染和/或急性肾上腺功能不全与死亡率增加有关。原发性和继发性肾上腺功能不全均可发生急性肾上腺缺乏(肾上腺危象)。其发病率主要在回顾性研究中确定,在欧洲估计为 6-8/100 例患者/年。一项前瞻性研究报告称,肾上腺危象导致 0.5 例/100 例患者/年死亡。肾上腺功能不全的长期发病率尚未得到充分证实,未一致报道的心血管风险增加或骨质减少也可能是由于生理性糖皮质激素替代治疗。然而,几项原发性和继发性肾上腺功能不全的研究表明,生活质量发生了变化,包括身体和心理健康方面。